Sanofi Ends Development of Two Phase III Drugs - - BioPharm International

ADVERTISEMENT

Sanofi Ends Development of Two Phase III Drugs


Sanofi has discontinued development of two investigational drugs in Phase III development, iniparib, a drug to treat non-small cell lung cancer, and otamixaban, an anticoagulant, based on recent clinical results. Sanofi will take an after-tax change of $285 million for iniparib.

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Mallinckrodt to Acquire Questcor Pharmaceuticals
April 16, 2014
EMA Warns of Falsified Herceptin Vials
April 16, 2014
PhRMA Report Reveals Growth Trajectories and Policy Factors Affecting Biopharmaceutical Growth
April 11, 2014
American CryoStem and Rutgers University File Joint Patent on Stem Cell Platform
April 11, 2014
Center for Biologics Evaluation and Research Relocates
April 11, 2014
Author Guidelines

Click here